Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg
Completed
Mylan Pharmaceuticals
Phase 1
2002-12-01
The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg
tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg)
dose administration under fasting conditions.
Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg
Completed
Mylan Pharmaceuticals
Phase 1
2003-10-01
The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg
tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose
administration under fasting conditions.
Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg
Completed
Mylan Pharmaceuticals
Phase 1
2004-02-01
The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg
tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose
administration under fasting conditions.
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure
Terminated
University of Illinois at Chicago
Phase 4
2008-10-01
The purpose of this prospective, randomized, open-label study is to compare two diuretic
strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral
thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition
from IVB to continuous infusion (CI) loop diuretic.
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure
Terminated
Virginia Commonwealth University
Phase 4
2008-10-01
The purpose of this prospective, randomized, open-label study is to compare two diuretic
strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral
thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition
from IVB to continuous infusion (CI) loop diuretic.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
